Brain metastases

Current Treatment Options in Oncology (Impact Factor: 3.24). 12/2001; 2(6):537-547. DOI: 10.1007/s11864-001-0075-8

ABSTRACT Metastatic tumors to the brain are an increasing cause of morbidity and mortality in patients with systemic cancers. Many
new therapies used to treat systemic cancers do not penetrate the central nervous system (CNS) and do not protect patients
from the development of brain metastases. Surgery, radiosurgery, and radiation therapy are all used to treat brain metastases.
It is in our opinion a mistake to use only one or two of these modalities to the exclusion of other(s). The role of systemic
chemotherapy is still limited, due to both the issues of drug delivery caused by the blood brain barrier and to the relative
resistance of many of these tumors to chemotherapy. Traditionally, brain metastases have been grouped together regardless
of the origin of the tumor and have been treated with a single algorithm. As we encounter more patients for whom treatment
of the brain metastases is an important determinant of survival, we must tailor our treatment strategies to individual tumor
types. Also, we must recognize differences in each tumor’s sensitivity to chemotherapy and radiotherapy and differences in
their biology.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Central nervous system (CNS) metastases from ovarian adenocarcinoma are uncommon. The long-term prognosis for these patients is poor, with studies reporting a mean survival of less than 12 months. We present a case involving a 57-year-old woman diagnosed and treated for primary ovarian cancer in 1994. She underwent optimal cytoreductive surgery and received adjuvant chemotherapy. In 1996, she was diagnosed with a right cerebellar metastatic lesion, and treated with surgery and whole-brain radiotherapy. She is currently 7 years post-treatment of her brain metastasis without evidence of recurrent disease. Brain metastases from primary ovarian cancer are a relatively rare finding. These patients have a poor prognosis, with studies reporting a mean survival of 12 months. However, the patient in this report remains disease-free since her treatment for metastatic disease. Aggressive surgical and radiation treatment for patients with isolated CNS metastases is reasonable.
    Gynecologic Oncology 04/2004; 92(3):978-80. DOI:10.1016/j.ygyno.2003.11.024 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Inoperable melanoma brain metastases are usually uniformly fatal, and complete response after cytotoxic therapy is rare. Case report: A patient with multiple inoperable melanoma brain metastases was treated with 6 cycles of oral temozolomide (300 mg once daily over 5 days every 28 days). A complete response was documented by magnetic resonance. Conclusions: The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases.
    Onkologie 05/2004; 27(2):171-4. DOI:10.1159/000076908 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Brain metastases are an increasingly frequent complication of cancer. Advances in diagnosis and treatment have led to wider indications for surgery. We present a single-institution series of 177 patients and discuss our results with regard to the literature. Special focus is on patients with advanced age, multiple brain metastases, extracranial metastases, and brain metastasis recurrence. All patients underwent craniotomy for the resection of solid tumor brain metastases between 1994 and 2001 in our department. Perioperative morbidity and mortality as well as survival were evaluated. The median patient age was 59 years (range 32-86 years). In 177 patients, 348 brain metastases were detected, of which 68.0% were supratentorial and 32.0% were infratentorial. According to univariate analysis, the following parameters were significantly associated with prolonged patient survival: (1) age <70 years, (2) one to three intracranial metastases, (3) favorable postoperative performance, (4) resection of all intracranial lesions, and (5) recraniotomy for brain metastasis recurrence. In contrast, the presence of extracranial metastases, metachronous diagnosis, and solitary brain metastases had no influence on survival. As expected, younger age and limited number of brain metastases (up to three) are favorable prognostic factors. Remarkably, the presence of extracranial metastases had no influence on patient survival.
    Neurosurgical Review 05/2005; 28(2):115-9. DOI:10.1007/s10143-004-0364-3 · 1.86 Impact Factor